Skip to main content
Clinical Trials/NCT06270966
NCT06270966
Not Yet Recruiting
N/A

Cognitive Remediation Virtual Reality Tool a Recovery-oriented Project for People With Mild Cognitive Impairment: a Feasibility Randomized Clinical Trial

University of Cagliari1 site in 1 country30 target enrollmentMarch 7, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Mild Cognitive Impairment
Sponsor
University of Cagliari
Enrollment
30
Locations
1
Primary Endpoint
Side effects; Dropout rates; Proportion of recruited participants among those considered eligible
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The need to promote research in active aging trough multidisciplinary and innovative approaches is strongly indicated by the European Union. Our study aims to assess the feasibility and provide a preliminary measure of effectiveness for an intervention using immersive virtual reality (VR) technology for cognitive remediation (CR) in individuals with Mild Cognitive Impairment (MCI)

Detailed Description

The European Union emphasizes the need to promote research in active aging trough multidisciplinary and innovative approaches, addressing challenges related to neurodegenerative diseases in old adults. Our study aims to assess the feasibility and provide a preliminary measure of effectiveness for an intervention using immersive virtual reality (VR) technology for cognitive remediation (CR) in individuals with Mild Cognitive Impairment (MCI). Methods: A feasibility randomized controlled clinical trial will involve 30 individuals who are over 65 years old, both sex, who have received the diagnosis of MCI, randomly assigned to experimental condition or control group. Both groups will continue to receive standard pharmacological therapy (TAU). The experimental group will undergo a 3-months cognitive remediation program with fully immersive VR with two sessions per week (each session of sixty minutes). The control group will continue with TAU. Feasibility will be assessed based on tolerability, including dropout rates and acceptability, (proportion of recruited participants among those considered eligible) and side effects. The preliminary measures of effectiveness will be evaluated on cognitive functions, quality of life, biological and social rhythms, anxiety and depressive.

Registry
clinicaltrials.gov
Start Date
March 7, 2024
End Date
December 1, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mauro Giovanni Carta

Principal Investigator

University of Cagliari

Eligibility Criteria

Inclusion Criteria

  • age 65 and above, a diagnosis of MCI based on DSM-IV criteria \[American Psychiatric Association, 2000\]

Exclusion Criteria

  • failure to meet inclusion criteria, a diagnosis of epilepsy or severe visual impairments due to potential risks associated with extensive virtual reality stimulation, and severe illnesses impeding bi-weekly intervention attendance

Outcomes

Primary Outcomes

Side effects; Dropout rates; Proportion of recruited participants among those considered eligible

Time Frame: T0 (0 weeks); T1 (12 weeks)

Feasibility will be assessed based on tolerability, including dropout rates and acceptability, which considers the proportion of recruited participants among those considered eligible and side effects.

Secondary Outcomes

  • Short Form Health Survey, 12 items (SF-12)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Addenbrooke's Cognitive Examination (ACE-R)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Brief Social Rhythms Scale (BSRS)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Patient Health Questionnaire (PHQ-9)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Generalized Anxiety Disorder-7 item (GAD-7)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Matrix test(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Trail Making Test (TMT)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Stroop Test(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Rey Figure Test(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Frontal Assessment Battery (FAB)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Rey's Word Test(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Digit Span(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))
  • Cognitive Estimates Test (CET)(T0 (0 weeks); T1 (12 weeks); T2 (36 weeks); (72 weeks))

Study Sites (1)

Loading locations...

Similar Trials